{"id":"W3014488763","doi":"10.1002/jha2.4","title":"Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib","year":2020,"lang":"en","type":"article","venue":"eJHaem","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Bortezomib; Medicine; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Placebo; Hazard ratio; Interim analysis; Adverse effect; Surgery; Gastroenterology; Oncology; Randomized controlled trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004710201,0.0005939218,0.00255674,0.000282694,0.0001096172,0.00003691051,0.0001443591,0.0001153312,0.00007378933],"category_scores_gemma":[0.0006506631,0.0003345686,0.0001016142,0.0006273462,0.0003636848,0.0002223421,0.00006659671,0.0004640046,0.000005910652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001211157,"about_ca_system_score_gemma":0.0002171873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006213443,"about_ca_topic_score_gemma":0.0006180233,"domain_scores_codex":[0.9962592,0.0005633219,0.0007940279,0.0008215549,0.0009469695,0.0006149574],"domain_scores_gemma":[0.9972893,0.0007026774,0.0004294477,0.0005614915,0.0003661,0.0006510086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5690397,0.005644873,0.4195218,0.00009954561,0.001380249,0.0005294092,0.001856972,0.00001081893,0.00005700888,0.000001750237,0.00002387894,0.001834009],"study_design_scores_gemma":[0.7714443,0.03996286,0.1843735,0.0002869939,0.0008722325,0.00001604902,0.0009487294,0.001559062,0.0002294342,5.216477e-7,0.00002409271,0.0002821889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860534,0.0003790717,0.00004580975,0.0001940019,0.00001199092,0.0129256,0.00003970804,0.00009056958,0.0002598499],"genre_scores_gemma":[0.9976381,0.0000526191,0.0008914042,0.00008515055,0.00003269094,0.0008258062,0.0001798878,0.0001002278,0.0001941107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2351483,"threshold_uncertainty_score":0.9999107,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01771398157137364,"score_gpt":0.27255795567471,"score_spread":0.2548439741033364,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}